Abstract The incidence of type 2 diabetes mellitus (T2DM) among children and adolescents has been rising. This condition is associated with obesity, and it's prevalence is higher among minority or female youth. Lifestyle modification including diet and exercise is only successful in a small proportion of patients; therefore, pharmacotherapy approaches are needed to treat T2DM among youth. Currently, in the USA, only metformin and insulin are approved for the treatment of T2DM in children. However, several antihyperglycemic agents including exenatide, glimepiride, glyburide, liraglutide, pioglitazone, and rosiglitazone are also used off-label in this population. Moreover, a number of clinical trials are ongoing that are aimed at addressing the safety and efficacy of newer antihyperglycemic agents in this population. Little is known about the safety, efficacy, or pharmacokinetics of antihyperglycemic agents in children or adolescents. Our ability to predict the pharmacokinetics of these agents in youth is hampered first by the lack of information about the expression and activity of drug-metabolizing enzymes and transporters in this population and second by the presence of comorbid conditions such as obesity and fatty liver disease. This article reviews the prevalence of obesity and T2DM in children and adolescents (youth). We then summarize published studies on safety and effectiveness of antihyperglycemic medications in youth. Drug disposition may be affected by age or puberty and thus the expression and activity of different pathways for drug metabolism and xenobiotic transporters are compared between youth and adults followed by a summary of pharmacokinetics studies of antihyperglycemic agents currently used in this population.
Introduction
In the past two decades, the incidence of type 2 diabetes mellitus (T2DM) in children has substantially increased. This increase is seen mostly in minority youth and is highly correlated with the presence of obesity [1] . The number of overweight children in the USA has more than doubled over the past 30 years, resulting in an increase in insulin resistance and T2DM [2] . Other pediatric-specific risk factors for T2DM include being overweight, a family history of diabetes, and development of insulin resistance [2] . In addition, children who were not breastfed [3] or had low birth weight [4] may have an increased risk of T2DM. For example, in a Swedish study, individuals with lower birth weight had a threefold increased risk of T2DM by the age of 60 years [1] . Although most cases of T2DM are polygenic, a genetic locus on chromosome 2, Non-InsulinDependent Diabetes Mellitus (Common, Type 2) 1 (NIDDM1 gene), accounts for 30% of genetic susceptibility to this disease [1] .
Due to the increased prevalence, it is evident that more research is needed on T2DM in children. An epidemiological study called SEARCH for Diabetes in Youth identified the overall annual incidence rate of T2DM as 8.1 per 100,000 person-years in ages 10-14 years and 11.8 per 100,000 person-years in ages 15-19 years [5] . An agespecific annual incidence of 7.2 per 100,000 was found in Ohio in 1994, where one-third of all new cases of diabetes in ages 10-19 years was identified as T2DM [1] . Notably, for every male patient, 4-6 female patients are affected suggesting that T2DM in youth is more common in the female population [1] .
Similar to adults, the onset of T2DM in children is clinically manifested as polyuria, polydipsia, and polyphagia. Other manifestations include hypertension, lipid abnormalities, and acanthosis nigricans [2] . According to the American Diabetes Association, the primary method of prevention is to target modifiable risk factors such as weight loss through reduced caloric intake and increased physical activity. However, these lifestyle modifications may only be successful on a small scale [5] .
Pharmacologic treatment with antihyperglycemic agents may be necessary to treat T2DM in children [1] . At this time, only metformin and insulin are approved by the US Food and Drug Administration (FDA) for children with T2DM [6, 7] . More research is needed on the safe and effective use of other antihyperglycemic agents in this population [2] .
Search Strategy
The published literature was searched utilizing PubMed using search terms such as ''type 2 diabetes'' AND ''children'' with terms including ''pharmacotherapy'', ''therapy'', ''antidiabetic agents'', ''antihyperglycemic agents'', ''pharmacokinetics'', ''pharmacodynamics''. Relevant publications were reviewed, summarized, and included in this review. Moreover, the website ClinicalTrials.gov (https://clinicaltrials.gov/) was searched using the term ''type 2 diabetes'' and limiting the age range to Age Group ''birth -17 years''. Past and ongoing studies involving a pharmacotherapy approach were identified, and the drug name was included in PubMed searches.
Prevalence and Pathophysiology of Type 2
Diabetes Mellitus (T2DM) in Children and Adolescents
The World Health Organization's definition of adolescence is between the ages of 10 and 19 years old, which is associated with the onset of physiologically normal puberty until adult identity and behavior are established [8] . The prevalence of T2DM is higher in minority youth such as African American, Hispanic, Asian/Pacific Island, and American Indian youth in the USA. This disease often occurs in obese 12-to 19-year-old adolescents [9] [10] [11] [12] [13] [14] [15] [16] [17] and is more common in female than male youth, which is opposite to the gender pattern in adults [18, 19] . Several social, behavioral, and environmental risk factors are associated with the manifestation of T2DM [20, 21] . The incidence of insulin resistance is significantly higher in youth with moderate or severe obesity, and it is significantly more prevalent in obese black children than in obese white children [22] .
The peak incidence of T2DM in children is around the age of mid-puberty due to increasing secretion of growth hormone (GH) leading to insulin resistance. Secretion of leptin, adiponectin, and tumor necrosis factor-a by adipose tissue may also change insulin secretion and sensitivity [23] . The major differences between children and adults at the onset of T2DM include the following: (1) children have a higher body mass index (BMI), causing greater insulin resistance; (2) children have a lower glycated hemoglobin (HbA 1c ) due to a shorter latency period and less time for the development of glucose dysregulation; and (3) a higher incidence of diabetic ketoacidosis (DKA) and glucose toxicity exist in children at diagnosis [24] .
Clinical Presentation of T2DM in Youth
Obesity is the most important predictor for the development of T2DM in children [18] ; however, many obese children are asymptomatic at the time of diagnosis [25] . In the mildest form, an asymptomatic child is usually diagnosed through routine screening by detection of hyperglycemia and glycosuria that is usually without ketonuria. Absent or mild polyuria and polydipsia, and little or no weight loss are other features of an asymptomatic child with T2DM. Because children with autoimmune type 1 diabetes can also be obese [26] , it is important to distinguish between type 1 diabetes and T2DM by measuring fasting insulin, C-peptide [26, 27] , and islet autoantibodies [26, 28] .
In children with full-blown T2DM, the most severe form of polyuria, polydipsia, weight loss and ketonuria are often present [18, 29, 30] . Moreover, DKA can occur in approximately 25% of adolescent patients with T2DM [14] . Serious complications such as hyperosmolar hyperglycemic non-ketotic syndrome (HHNS) can commonly occur among youth with T2DM, which may cause increased fatality [31] . Additionally, in female patients, polycystic ovarian syndrome may also be present [29] . Other complications such as lipid disorders and hypertension also occur more frequently in children with T2DM [30] . The presence of different co-morbidities in these children necessitates administration of other medications such as drugs to treat high blood pressure and hyperlipidemia, resulting in increased incidence of drug-drug interactions and adverse effects.
Treatment of T2DM in Youth
Management of T2DM in children and adolescents is limited to lifestyle modifications and pharmacotherapy [6] . Diet and exercise are usually recommended as the initial interventions [4, 28] ; however, most pediatric patients respond poorly to lifestyle modification programs [4, 35] . The addition of metformin has clinical advantages of decreasing weight, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels in children without causing hypoglycemia [32] . If glycemic control is not sufficient on metformin, long-acting insulin may be recommended as an effective, adjunctive agent. Nevertheless, this regimen may not achieve therapeutic goals, and hence other antihyperglycemic agents may be needed [29] . Although few studies have been performed in children with T2DM [33] , in this article we evaluate available studies on the efficacy, safety, and pharmacokinetics of antihyperglycemic agents used in the pediatric population.
Safety and Efficacy of Antihyperglycemic Agents in Youth
In addition to metformin, which is FDA-approved, several other antihyperglycemic agents are used off-label in the pediatric population. Available clinical trials on safety and efficacy are summarized below and in Table 1 .
Metformin Monotherapy
In a randomized, double-blind, placebo-controlled trial, the safety and efficacy of metformin were evaluated in 82 individuals aged 10-16 years for up to 16 weeks. The selected dose was 500 mg twice daily which was titrated to 1000 mg twice daily if fasting plasma glucose (FPG) was [126 mg/dL. In addition to decreasing both HbA 1c and FPG, a reduction in body weight and improvement of the lipid profile was observed. Adverse events (AEs) were similar to those reported in adults treated with metformin. Therefore, metformin appears to be safe and effective for the treatment of T2DM in pediatric patients [34] . In another study, the effect of metformin therapy on body weight was evaluated. One hundred severely obese, insulin-resistant 6-12 year olds were randomized to metformin 1000 mg (n = 53) or placebo (n = 47) twice daily for 6 months. Metformin had modest but considerable effects on body weight, body composition, and glucose homeostasis [35] . In another cohort of adolescent T2DM participants (n = 1092), parameters such as HbA 1c , BMI, LDL-C, triglycerides, and blood pressure were improved. Treatment with metformin provided short-term improvements in glycemic control and cardiometabolic risk factors, and nearly all insulin-treated youth were eventually weaned off insulin (Table 1 ) [36] . Although metformin studies reported clinical benefit, evidence from the TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study suggests that metformin monotherapy is ineffective for maintaining glycemic control in about 50% of patients within 1 year of treatment. Pancreatic b cell function deteriorated at a rate of 20-35% per year in the participants of the TODAY study, which is considerably higher than 7-11% decline per year in adult studies [37] [38] [39] . Over 4 years, rates of hypertension and microalbuminuria increased from 11.6% baseline to 33.8% and from 6.3% baseline to 16.6%, respectively. Only 55.9% of the youth met the goal for LDL-C level after 3 years, and 13.7% had developed retinopathy.
Bariatric surgery can be the last resort therapeutic intervention for the treatment of T2DM even in children and adolescent patients [40] . The effect of gastric bypass surgery on the absorption and bioavailability of metformin has been investigated in adult patients. Bioavailability of metformin in Roux-en-Y gastric bypass (RYGB) adult patients was increased by 50% [41] . In addition, the apparent volume of distribution (V d ) and renal clearance [41] values were higher. Glucose levels were significantly lower in bypass subjects; however, these results were likely due to baseline differences in glucose levels instead of metformin absorption. Because RYGB is also a treatment option in youth with T2DM, further research is needed on the effect of this procedure on pharmacokinetics of antihyperglycemic agents in this population.
Metformin and Glimepiride
Two additional efficacy and safety trials were conducted in the adolescent population with T2DM [42, 43] . The first trial compared glimepiride (1-8 mg/day) and metformin (500-1000 mg twice daily) for 24 weeks (12-week titration and 12-week maintenance periods) [42] . Patients with T2DM on metformin therapy were randomized to receive glimepiride ? metformin versus metformin monotherapy. The incidence of adverse events was 7.7% for glimepiridetreated patients and 13.4% for metformin-treated patients [42] (Table 1) . Reductions from baseline HbA 1c were observed in both the glimepiride (-0.54%; p = 0.001) and metformin (-0.71%; p = 0.0002) groups. Further efficacy results found 42.4% of glimepiride-treated and 48.1% of metformin-treated patients achieved HbA 1c of \7% at week 24. Secondary findings observed no differences in self-monitored glucose levels, lipid concentrations, or hypoglycemia incidence between the antihyperglycemic agents. However, the mean change in BMI from baseline was significantly different (?0.26 vs. -0.33 kg/m 2 ) in the glimepiride and metformin groups, respectively. Even though glimepiride patients had greater weight gain, the researchers concluded the two drugs had comparable safety and similarly reduced HbA 1c [42] .
Metformin and Glyburide
In another study, metformin monotherapy and glyburide (glibenclamide) monotherapy were compared with metformin ? glyburide in 9-to 16-year-old children with T2DM. After 26 weeks, the mean HbA 1c declined in all three groups-metformin/glyburide, metformin alone, and glyburide alone-but the combination therapy failed to show superiority over the monotherapies [44] .
Metformin and Rosiglitazone
In the TODAY study, the efficacy of three treatment regimens-metformin alone, metformin ? rosiglitazone 4 mg twice daily, or metformin ? lifestyle intervention-were compared [43] . Patients aged 10-17 years with T2DM who were treated with metformin at doses up to 1000 mg twice daily for at least 2 months were randomized into different groups. Evaluation of glycemic control defined as an HbA 1c level of \8% was the primary objective. Of the 699 study participants, 45.6% achieved glycemic control for an Mild GI symptoms, nausea, diarrhea, hypoglycemia
; HbA 1c and FPG and no effect on weight [46] bid twice daily, FPG fasting plasma glucose, GI gastrointestinal, HbA 1c glycated hemoglobin, LDL-C low-density lipoprotein cholesterol, ; indicates decrease, $ indicates no change average of 3.86 years. Failure rates were 51.7, 38.6, and 46.6% for metformin alone, metformin ? rosiglitazone, and metformin plus lifestyle intervention, respectively. The proportion of patients free of glycemic failure was significantly better for metformin ? rosiglitazone than metformin alone (p = 0.006). There was no statistically significant difference when metformin ? lifestyle intervention was compared with metformin alone. Subgroup analysis showed that metformin ? rosiglitazone was more effective in girls than in boys [43] . Further concerns regarding serious adverse effects reported in adults being treated with thiazolidinediones limit the use of rosiglitazone in children and adolescents [6] .
Liraglutide
Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, is used off-label in adolescents with T2DM [45] . In a publication by Klein et al. [46] , liraglutide administration was compared with placebo in T2DM adolescents aged 10-17 years who were treated with diet/exercise alone or with metformin. No serious adverse effects were observed, including severe hypoglycemia. Mild gastrointestinal adverse effects were more common in the liraglutide group [46] , although unlike adults, no weight loss was observed in this population [45] . A subsequent efficacy and safety trial of liraglutide compared with metformin is currently recruiting participants within the pediatric population (ClinicalTrials.gov identifier: NCT01541215) [81] .
Ongoing Studies with Other Agents
According to ClinicalTrials.gov, a safety and efficacy study (NCT01554618) of another GLP-1 agonist, exenatide once-weekly, is currently underway [82] . Further studies are also ongoing aimed at assessing the use of dipeptidyl peptidase 4 (DPP-4) inhibitors (alogliptin, linagliptin, sitagliptin, and saxagliptin) and sodium-glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin, dapagliflozin, empagliflozin) in the pediatric population, but limited published results were available as of July 2016.
Pharmacokinetic Considerations in the Use of Antihyperglycemic Agents in Youth
Since T2DM mostly occurs during later stages of adulthood, few studies are available on the pharmacokinetics of antihyperglycemic agents in children or adolescents. In children, several factors including the developmental age of the child, severity of obesity, and degree of insulin resistance can cause changes in pharmacokinetics. It is difficult to predict the pharmacokinetics of each drug in T2DM children across the age range of 10-19 years, especially as puberty occurs during the same period. The presence of co-morbid conditions such as non-alcoholic fatty liver disease (NAFLD) [47] and hyperlipidemia further complicates this relationship. In the absence of formal pharmacokinetic studies, predictive tools including physiologically based pharmacokinetic (PBPK) modeling, as implemented in Simcyp Ò (Certara, Princeton, NJ, USA) or GastroPlus TM (Simulations Plus, Inc., Lancaster, CA, USA), will be highly advantageous for predicting the pharmacokinetic parameters and required drug dose in a T2DM youth.
Current knowledge of the effect of disease state (i.e., obesity, diabetes, fatty liver) on pharmacokinetics is incomplete but advances in PBPK will eventually empower pharmacokinetic prediction tools when a combination of several disease states are present. Figure 1 depicts the pharmacokinetic pathways of the majority of antihyperglycemic agents that are used in children and adolescents. Fortunately, based on the elimination pathways, the drugdrug interaction potential for most antihyperglycemic agents used in children and adolescents is low to intermediate (Table 2) . However, altered expression and activity of metabolizing enzymes or transporters in children cannot be dismissed and nor can the fact the other comorbid conditions such as obesity, diabetes, and NAFLD can influence such pathways.
Influence of Diabetes and Associated Conditions on Drug Disposition
Diabetes mellitus and associated conditions such as obesity and NAFLD variably influence pharmacokinetics and the expression and activity of drug-metabolizing enzymes (DMEs) and xenobiotic transporters [48] [49] [50] . However, only anecdotal information is available on the effect of diabetes on pharmacokinetics in children and youth with diabetes. As reviewed previously [50, 51] , pathological damage associated with hyperglycemia can influence all aspects of drug disposition. First, drug absorption can be delayed because of a delayed gastric emptying time and changes in the gastrointestinal pH and motility. Second, plasma protein binding of drugs is altered because of an increased concentration of glycated endproducts (i.e., increased albumin glycation) and dyslipidemia. Third, the expression and activity of several DMEs is altered, including significantly lower expression and activity of cytochrome P450 (CYP) 3A4 [48] and uridine diphosphate-glucuronosyltransferase (UGT) 2B7 [49] . Fourth, renal excretion of drugs is reduced once kidney function is compromised because of diabetic nephropathy [50] . These changes will collectively influence the drug concentration and may lead to altered effect. Moreover, the effect of diabetes on pharmacokinetics cannot be viewed in isolation from other co-morbid conditions such as obesity [52] and NAFLD [53] , both of which are known to influence pharmacokinetics.
Absorption, Distribution, Metabolism, and Excretion in Children and Adolescents
Generally, physiological differences in childhood and adolescence can affect the absorption, distribution, metabolism, and excretion (ADME) of various drugs [54, 55] . A systematic review of 20 pharmacokinetics studies in obese children identified significantly altered pharmacokinetics in 65% of the cases. Despite this, consensus about weightbased dosing in obese children is currently lacking [56] .
Absorption
Maturation changes in gastric and intestinal pH, gastrointestinal emptying time, circulation, enzyme activity, and the differences in gastrointestinal flora may influence drug absorption [55, 57] .
Distribution
An increased total body water:body fat ratio, decreased binding proteins in plasma, and differences in tissue binding will affect V d . The alteration in V d will depend on the physiochemical characteristics of a given drug [55, 57] .
Renal Elimination
Renal function is 25-30% of adult values at birth, increasing to 50-75% by 6 months and to adult level by age 2-3 years. Therefore, reduction of the drug dose must be considered for drugs undergoing renal elimination, although it is unlikely that T2DM will develop at such young age [55, 58] .
Maturation of Drug-Metabolizing Enzymes and Transporters
After birth, the activities of DMEs undergo change due to physical and sexual maturation. CYP enzymatic activity is about 50-70% of adult levels at birth but will reach and exceed adult values afterward. By puberty, as hormone levels increase, CYP enzymatic activity reaches adult levels.
The expression of DMEs is related to the concentration of hormones such as growth and/or sex hormones. Puberty is marked by a coordinated and hormonally regulated physical and sexual maturation. Typically, the concentration of gonadotropins, sex steroids, adrenal androgens, and GH is increased during puberty, which may differentially affect the expression of different DMEs between male and
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Basolateral membrane female. Increases in GH and insulin-like growth factor-1 (IGF-1) are known to reduce the expression of CYP1A2, as characterized by the caffeine breath test. CYP1A2, CYP2B6, CYP2C19, and CYP2E1 expression is mostly mediated by estrogen, whereas others, such as CYP3A4, are mostly regulated by androgens and progesterone [59] . A decrease in global CYP450 activity, characterized by antipyrine pharmacokinetics, was noted in children and adolescents undergoing puberty [60] . Although CYP2C function is deficient in neonates [61] [62] [63] [64] , CYP2C enzymatic activity reaches adult levels by puberty. CYP activity is increased in children compared with adults, but it is not because of the amount of hepatic microsomal proteins. The activity of CYP1A2, CYP2C, and CYP3A is increased, but the reason for higher clearance in children than adults is still unclear [65] . A study evaluating catalytic activity of six CYP isozymes, CYP1A2, CYP3A4/3A5, CYP2C8, CYP2C9, and CYP2E1, did not find a difference in enzyme activity in pediatric livers (younger than 10 years) compared with adult livers [66] . Another study that investigated the effect of age, sex, and genetic polymorphism on the expression of CYP2C8 protein did not find any significant difference between livers from 10 to 19 year olds versus another age group [67] . A proposed explanation for the increased metabolic activity is the increased ratio of liver size to body size in children [55] . In addition to the effect of age on the maturation of CYP450 enzymes, the effect of obesity on metabolism must be considered as it concurrently occurs with T2DM in children.
Liver cell
Recently, Prasad and colleagues [68] have measured the expression of various transporters in the liver of neonates, children, adolescents, and adults using a targeted mass spectrometry based proteomics method. The expression of organic cation transporter (OCT) 1, organic anion-transporting polypeptide (OATP) 1B3, P-glycoprotein, and multidrug-resistance protein 3 (MRP3) proteins were agedependent. However, in the adolescent liver, only MRP3 expression was significantly lower than in adult liver [68] ( Table 2 ).
Pharmacokinetic Studies of Antihyperglycemic Agents in Youth
The information about pharmacokinetic properties of antihyperglycemic agents in youth is incomplete. However, several published studies do not indicate grossly different pharmacokinetic properties between adolescents and adults. 
Metformin
Metformin is eliminated in the urine and several OCTs play an important role in metformin disposition (Fig. 1) . No information is available on the expression of OCTs in kidneys from youth ( Table 2) . The pharmacokinetic properties of metformin were investigated in a study that included 32 subjects aged 12-16 years [34] ; metformin (500 mg) was given to the patients twice daily for 1 week. Pharmacokinetic parameters were determined by analysis of blood and urine samples, which were obtained over an 11-h period. The area under the plasma concentration-time curve (AUC), maximum (peak) plasma concentration (C max ), and elimination half-life (t ) values for metformin were 4.49 mgÁh/mL, 0.73 mg/mL, and 3.7 h, respectively. Systemic drug exposure (metformin AUC) in children was only 54% of that reported in adults with the same dosing [34] . Another study of single-dose metformin pharmacokinetics in patients 12-16 years of age showed a less than 5% difference in C max , AUC, and t when compared with healthy adult subjects [69] .
In another study, the pharmacokinetics of metformin in young, non-obese girls were investigated. The study population consisted of six 9-year-old girls who had a low birth weight and an early to normal onset of puberty. The dose of metformin 850 mg/day was received for 8 months. Blood samples were obtained from the girls before metformin intake and for 12 h afterward. The mean AUC was 21 mgÁh/L, with a C max of 3 mg/L, time to C max (t max ) of 2.5 h, t of 4 h, V d of 111 L, and clearance of 20 L/h. These values are comparable with those observed in adults [70] .
Glimepiride
In the glimepiride pediatric development study, the pharmacokinetics of a glimepiride 1 mg single dose were evaluated [42] . AUC, C max , and t max values were 338.8 ngÁh/mL, 102.4 ng/mL, and 1 h, respectively. Although negative correlations were observed between drug clearance and age and weight, this association did not warrant dose adjustment [42] . The pharmacokinetics of glimepiride have also been studied in obese adults and children [71] . Glimepiride, a CYP2C9 substrate, is metabolized to the active M1 hydroxyl metabolite. Hepatic expression of CYP2C9 is comparable between adolescents and adults ( Table 2) . Clearance of parent glimepiride and metabolite M1 was not significantly different in obese versus non-obese T2DM patients. Cumulative urine excretion of M1 over 24 h post-dose was 30% higher in obese than in non-obese subjects, while both groups received equal doses. Weight-normalized clearance values showed a slight decrease in CYP2C9-mediated clearance per kilogram of total body weight [71] .
Glyburide
A pharmacokinetic study was conducted for a combination therapy of glyburide/metformin and included 28 participants aged 10-16 years. Following the administration of a single glyburide/metformin 1.25/250 mg dose, blood samples were collected at selected timepoints over a 24-h period. AUC, C max , and t max values for glyburide were 167 ngÁh/mL, 41.3 ng/mL, and 1 h and for metformin were 3011 ngÁh/mL, 473 ng/mL, and 2 h, respectively. The pediatric pharmacokinetic parameters for the metformin/ glyburide combination were only slightly different from adult pharmacokinetic parameters [72] .
Pioglitazone
Pioglitazone is a CYP2C8 substrate that undergoes extensive hepatic biotransformation (Table 2) . A pharmacokinetic study assessed single and multiple doses of pioglitazone in 36 adolescents with T2DM [73] . Participants were aged 12-17 years and received once-daily doses of pioglitazone 15, 30, or 45 mg, and the pharmacokinetics were studied as a single dose or after receiving multiple doses for 15 days. Plasma concentrations of pioglitazone and active metabolites (M-III and M-IV) were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters of pioglitazone were not significantly different from those observed in adult patients. Accumulation of parent pioglitazone was negligible, but M-III and M-IV concentrations at steady state reached a three-fold higher concentration than the single dose concentration. Pioglitazone was well-tolerated in the study population yet seven of 37 subjects experienced drug-related AEs. These AEs were mild to moderate and were subsided when pioglitazone was discontinued.
Rosiglitazone
The pharmacokinetics of rosiglitazone were evaluated following administration of a single dose of 2 or 4 mg in patients aged 10-17 years. t max , apparent clearance (CL/F), and apparent volume of distribution after oral administration (V d /F) values were 1.5 h, 3.15 L/h, and 13.5 L, respectively. The predicted rosiglitazone AUC, based on twice-daily doses of 2 and 4 mg were 1520 and 3040 ngÁh/ mL, respectively, indicating dose linearity. Pediatric pharmacokinetic parameters were found to be consistent with data from adults [24] .
Exenatide
The pharmacokinetics and tolerability of a single subcutaneously administered dose of exenatide was investigated in T2DM adolescents [74] . Exenatide is predominantly eliminated by glomerular filtration after undergoing proteolytic degradation [75] . The study enrolled 13 patients aged 10-16 years who were treated with diet/exercise or a stable dose of metformin, a sulfonylurea, or a combination of metformin and sulfonylurea for at least 3 months before screening to receive a single dose of exenatide (2.5 or 5 lg) or placebo on three separate days [74] . Exposure to exenatide was two-fold higher in the 5 lg dose group than in the 2.5 lg group. AUC from time zero to 360 min (AUC 360 min ) and C max values obtained after the 5 lg dose were comparable with values obtained in adult studies with exenatide. Both doses significantly reduced postprandial glucose excursion as compared with placebo and resulted in a lower glucagon concentration. However, the concentration of serum insulin was not different [74] .
Liraglutide
Liraglutide is a long-acting GLP-1 agonist with a peptide structure. It is extensively metabolized predominantly by DPP-4 and neutral endopeptidases and is entirely eliminated renally as breakdown products. Liraglutide pharmacokinetics in youth were comparable with those in adults and showed a linear dose-concentration relationship. For a 1.8 mg subcutaneous injection dose, the liraglutide t max was 8 h, t was 12 h, and apparent clearance was 1.7 L/h [46] . Population pharmacokinetics analysis has been used to compare liraglutide pharmacokinetics obtained from one pediatric trial with two adult trials [76] . The geometric mean (95% confidence interval) of relative exposure (AUC) for pediatric/adult was 0.90 (0.78-1.03) [76] . Liraglutide exposure was significantly higher in subjects with lower body weight and was lower in male than female subjects [76] .
Dapagliflozin
The pharmacokinetics of dapagliflozin were studied in children and adolescents (10-17 years old) with T2DM [77] . Dapagliflozin inhibits SGLT2, and thereby significantly reduces glucose reabsorption in the kidney. Dapagliflozin is metabolized by UGT1A9 to a major metabolite, dapagliflozin 3-O-glucuronide, and this metabolite is inactive [77] . This route of metabolism is absent at birth but reaches the adult level by the age of 1 year [78] . Moreover, previous studies in liver from subjects with diabetes did not find a significant effect of diabetes on the UGT1A9 expression or activity [49] . Dapagliflozin was well-tolerated between the doses of 2.5 and 10 mg, and its pharmacokinetic properties did not differ significantly from those in adult patients.
Conclusions
There is a significant increase in the prevalence of obesity and T2DM among children and adolescents. The off-label use of antihyperglycemic agents appears to be unavoidable given the limited therapeutic options in this population. Metformin as monotherapy or in combination with other antihyperglycemic agents appears to be safe, and several clinical trials are underway to investigate the safety and effectiveness of other antihyperglycemic agents in youth with T2DM. The pharmacokinetic characteristics of antihyperglycemic agents can be influenced by age, maturity, and the presence of obesity, diabetes, or NAFLD. Conventional pharmacokinetic studies with a smaller number of subjects maybe of limited value because such studies may not capture the presence of all sources of variability.
